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DifferentiationMutations in the CDKL5 (cyclin-dependent kinase-like 5) gene are associated with a severe epileptic enceph-
alopathy (early infantile epileptic encephalopathy type 2, EIEE2) characterized by early-onset intractable sei-
zures, infantile spasms, severe developmental delay, intellectual disability, and Rett syndrome (RTT)-like
features. Despite the clear involvement of CDKL5 mutations in intellectual disability, the function of this pro-
tein during brain development and the molecular mechanisms involved in its regulation are still unknown.
Using human neuroblastoma cells as a model system we found that an increase in CDKL5 expression caused
an arrest of the cell cycle in the G0/G1 phases and induced cellular differentiation. Interestingly, CDKL5 ex-
pression was inhibited by MYCN, a transcription factor that promotes cell proliferation during brain develop-
ment and plays a relevant role in neuroblastoma biology. Through a combination of different and
complementary molecular and cellular approaches we could show that MYCN acts as a direct repressor of
the CDKL5 promoter. Overall our ﬁndings unveil a functional axis between MYCN and CDKL5 governing
both neuron proliferation rate and differentiation. The fact that CDKL5 is involved in the control of both neu-
ron proliferation and differentiation may help understand the early appearance of neurological symptoms in
patients with mutations in CDKL5.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Epilepsy, and in particular intractable epilepsy in infancy, often results
in an encephalopathic picture, known under these circumstances as an
epileptic encephalopathy. A severe epileptic encephalopathy (early infan-
tile epileptic encephalopathy type 2 (EIEE2); OMIN 300672) that is char-
acterized by intractable seizures with infantile spasms, intellectual
disability, and a Rett's syndrome (RTT)-like phenotype, is attributable to
cyclin-dependent kinase-like 5 mutations [4,6,18,29,37,42,44]. This con-
dition affects mostly girls and presents as an atypical RTT picture. It has
features of RTT, such as hyperventilation, hand stereotypies, and
kyphoscoliosis, hypotonia, that are superimposed on a typical epileptic
encephalopathy picture, with a clinical presentation dominated by early
seizures (onset before age six months) [4,14,37,41,44].acy and Biotechnology, Uni-
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-NC-ND license.The vast majority of RTT cases (>95%) are caused bymutations in the
MECP2 gene [2]. MECP2, which maps to chromosome Xq28 and is not
expressed from the inactive X chromosome, encodes for methyl-
CpG-binding protein 2 (MeCP2). Although patients carrying MECP2
mutations as well as Mecp2 knockout mice display a normal brain
cytoarchitecture without detectable loss of neurons [3,9], recent studies
indicate thatMeCP2 regulates the number and function of excitatory syn-
apses in the brain [7], suggesting that changes in neuronal functions may
represent the primary cause of the neurological phenotype in RTT.
The CDKL5 gene maps to chromosome Xp22 and encodes a protein
with kinase activity that is a member of the serine–threonine (Ser/Thr)
protein kinase family. It is a large protein which is composed by a con-
served N-terminal (Ser/Thr) kinase domain responsible for the catalytic
activity of the protein, and a large C-terminal region involved in the reg-
ulation of CDKL5 kinase activity [24] and in the nuclear localization of
the protein [5,28]. At the molecular level, the only in vitro CDKL5 sub-
strates identiﬁed so far are DNA methyltransferase 1 (DNMT1) and
MeCP2 [5,19,28], suggesting that CDKL5 may regulate DNAmethyla-
tion and the binding of MeCP2 to DNA. Interestingly, CDKL5 has been
also shown to play a role in the dynamic regulation of nuclear
speckles, which are implicated in the regulation of mRNA splicing
[35].
Studies in rodents have established that CDKL5 is expressed in the
developing and adult brain [8,36], suggesting a role of CDKL5 in
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can shuttle between the nucleus and the cytoplasm and that its sub-
cellular localization in the brain is developmentally regulated. Along
with its proposed function in the nucleus, CDKL5 appears to regulate
dendritic development, through a cytoplasmic mechanism involving
the BDNF-Rac1 signaling [8].
Despite the clear involvement of CDKL5 mutations in intellectual
disability, the function/s of this protein and the molecular mecha-
nisms involved in its regulation are poorly unknown. Herein, we
show that CDKL5 expression affects neuronal proliferation and differ-
entiation, two processes closely related during brain development,
and that CDKL5 is negatively regulated by MYCN, a key player in neu-
ronal development.
2. Materials and methods
2.1. Cell cultures
Human neuroblastoma cell lines SH-SY5Y and SKNBE, obtained
from ATCC (Manassas, VA, USA), and human Tet21/N cells, derived
from SHEP neuroblastoma cell line that stably express MYCN under
the control of tetracycline (Tet-off) [26], were maintained in
Dulbecco Modiﬁed Eagle Medium (DMEM) supplemented with 10%
heat-inactivated FBS, 2 mM of glutamine and antibiotics (penicillin,
100 U/ml; streptomycin, 100 μg/ml), in a humidiﬁed atmosphere of
5% of CO2 in air at 37 °C. Cell medium was replaced every 3 days
and the cells were sub-cultured once they reached 90% conﬂuence.
SH-SY5Y cells were transfected with the plasmid pCMV14-3XFLAG-
MYCN that contains the MYCN gene under the control of the human
cytomegalovirus promoter, and neoR, that confers neomycin resis-
tance. Clones were selected in the presence of 600 μg/ml of G418.
The Tet21/N cells were treated with tetracycline at a ﬁnal concentra-
tion of 2 μg/ml for the indicated time.
Primary cultures of cerebellar granular cell precursors (GCPs)
were prepared from the cerebella of 7-day-old C57BL/6J mice as pre-
viously described [15]. Brieﬂy, cerebella were removed and dissected
from their meninges in Krebs buffer containing 0.3% BSA. Tissue was
dissociated with trypsin at 37 °C for 15 min and triturated 15 times
using a Pasteur pipette in a DNAase/soybean trypsin inhibitor solu-
tion. Dissociated cells were plated on poly-D-lysine (20 μM, Sigma)-
coated dishes at a density of 2×103 cells/mm2 and maintained in
basal modiﬁed Eagle's medium (BME) (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum, 25 mM KCl, 2 mM gluta-
mine and 0.05 mg/ml gentamicin (Sigma).
2.2. Plasmids
Human CDKL5 cDNA was kindly provided by Marsha Rich Rosner
(University of Chicago) [24], CDKL5 cDNA was PCR ampliﬁed and
cloned into pCMV14–3xFLAG plasmid (Sigma). CDKL5-3xFLAG se-
quence was subcloned into the bicistronic pIRES2-EGFP plasmid
(Clontech) to obtain a GFP and CDKL5-FLAG co-expression vector
(pGFP/CDKL5-FLAG).
2.3. Immunocytochemistry
For cell proliferation analyses SH-SY5Y cells were plated onto
poly-D-lysine coated slides in 6-well plated at density of 3×105 cells
per well and transfected with 3 μg of CDKL5-FLAG expression plasmid
using lipofectamin (Roche). Twenty-four hours after transfection cells
were ﬁxed in a 4% paraformaldehyde 4% glucose solution at 37 °C for
30 min. For immunoﬂuorescence studies the following antibodies
were used. Primary antibodies: anti-Ki-67 rabbit monoclonal (1:100,
Thermo Scientiﬁc), anti-BrdU rat monoclonal (1:100, AbD Serotec),
anti-cleaved caspase-3 (asp175) rabbit polyclonal (1:100, Cell Signal-
ing Technology), anti-β-tubulin III rabbit polyclonal (TubJ, 1:500,Sigma) and anti-FLAG M2 mouse monoclonal (1:1000; Sigma).
Secondary antibodies: FITC-conjugated anti-rat antibody (1:200,
Jackson Immuno Research Laboratories), FITC-conjugated anti-rabbit
antibody (1:200, Jackson Immuno Research Laboratories) FITC-
conjugated anti-mouse antibody (1:200, Jackson Immuno Research
Laboratories) and Cy3-conjugated anti-rabbit antibody (1:200, Jack-
son Immuno Research Laboratories). Double immunoﬂuorescence
images, taken from randommicroscopic ﬁelds (10–12 for each cover-
slip), were superimposed and used to determine the labeling index
(LI), deﬁned as percentage of cells co-labeled with: anti-BrdU and
anti-FLAG or anti-cleaved caspase-3 and anti-FLAG or anti-Ki-67 and
anti-FLAG antibodies.
In each experimental condition we randomly analyzed a total of
600 cells. Fluorescence images were taken on an Eclipse TE 2000-S
microscope (Nikon, Tokyo, Japan) equipped with a digital camera
Sight DS-2MBW (Nikon).
2.4. Western blotting
The following antibodies were used: anti-CDKL5 (1:500; Sigma),
anti-FLAG M2 (1:1000; Sigma) and anti-GADPH (1:1000; Sigma).
For the preparation of total cell extracts, cells were lysed in RIPA
lysis buffer (Tris–HCl 50 mM, NaCl 150 mM, Triton X-100 1%, sodium
deoxycholate 0.5%, SDS 0.1%, protease and phosphatase inhibitors
cocktails 1%; Sigma). For the preparation of nuclear extracts cells
were allowed to swell and lysed in hypotonic buffer (Hepes 10 mM,
NaCl 50 mM, EDTA 1 mM, NP-40 0.1%, DTT 1 mM, PMSF 1 mM, pH
8) for 10 min at 4 °C. After centrifugation, nuclei were extracted
with hypertonic salt buffer (Hepes 20 mM, NaCl 420 mM, EDTA
1 mM, DTT 1 mM, glicerol 10%, PMSF 1 mM, pH 8). Cell extracts
were immediately processed by Western blot or kept frozen (−80 °C)
until assayed. Sample protein concentration was estimated by the
Lowry method [25]. Equivalent amounts (50 μg) of protein were
subjected to electrophoresis on a 10% SDS-polyacrylamide gel. Densito-
metric analysis of digitized images was performed with Scion Image
software (Scion Corporation, Frederick, MD, USA) and intensity for
each band was normalized to the intensity of the corresponding
β-actin or GAPDH band.
2.5. Analysis of neurite outgrowth
For differentiation analyses neuroblastoma cells were plated onto
poly-D-lysine coated slides in a 24-well plated at density of 2×104
cells per well. After 24 h of cell plating, differentiation was induced
by retinoic acid (RA; 10 μM) for the indicated time. This treatment
was replaced each 2 days to replenish RA in culture media. Phase con-
trast photographs of the cultures were taken at various time intervals
with an Eclipse TE 2000-S microscope (Nikon, Tokyo, Japan)
equipped with an AxioCam MRm (Zeiss, Oberkochen, Germany) dig-
ital camera. Ten different areas were randomly selected and neurite
outgrowth was measured using the image analysis system Image
Pro Plus (Media Cybernetics, Silver Spring, MD 20910, USA). Only
cells with neurites longer than one cell body diameter were consid-
ered as neurite-bearing cells. All experiments were performed at
least three times. In each experiment we analyzed a total of around
450 cells. The total length of neurites was divided for the total num-
ber of cells counted in the areas.
2.6. Flow cytometric analysis
SH-SY5Y cells were harvested 24 h after transfection with pGFP or
pGFP/CDKL5-FLAG plasmids, collected by trypsinization, pelleted and
resuspended in phosphate buffered saline (PBS) to a ﬁnal concentra-
tion of 1×106 cells/ml. Transfected cells were then analyzed on a
ﬂow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA, USA)
and sorted by GFP ﬂuorescence (detection ﬁlter set at 525 nm). Cell
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Untransfected SH-SY5Y cells were used to establish a threshold for
green ﬂuorescence (up to 102 arbitrary ﬂuorescence units in a typical
case), and which was taken as a threshold for positivity (Fig. 4C). For
differentiation analysis an aliquot of GFP sorted cells was plated in
6-well at the density of 3×105 cells per well in the presence or ab-
sence of RA (10 μM).
For cell cycle analysis cells were ﬁxed in 70% ethanol in PBS at−20 °C
for at least 1 h, washed several times with cold PBS, treated with RNaseA
(50 μg/ml) for 30 min at 37 °C and incubated with propidium iodide
(30 μg/ml). GFP-positive and -negative populations were analyzed sepa-
rately for DNA content (ﬁlter set at 675 nm) and assigned to speciﬁc
cell-cycle phases by applying the Cell Quest Software (Becton Dickinson,
San Jose, CA, USA).
2.7. Small interfering RNA assay
The siRNA oligonucleotides used for silencing CDKL5 were pur-
chased from QIAGEN and were: Hs-CDKL5-5 cat. No:SI02223116
(sense; Si1) and Hs-CDKL5-10 cat. No:SI004437244 (sense; Si2). Con-
trol cells were transfected with a scramble siRNA duplex; AllStars
Negative Control siRNA (siSCR QIAGEN), which does not present ho-
mology with any other human mRNAs. SH-SY5Y cells were
transfected with HiPerFect Transfection Reagent (QIAGEN) with
50 nM siRNA (ﬁnal concentration). For differentiation experiments
retinoic acid was added to the cells 6 h post transfection and the
cells harvested after further 42 h. For proliferation experiments
10 μM BrdU was added to the cells 46 h post transfection and the
cells harvested after further 2 h.
2.8. Quantitative real time PCR and standard reverse transcription-PCR
RNA samples were prepared using Tri-Reagent (Sigma) and
treated with DNase (DNA-freeTM; Ambion). Reverse transcription
was performed using a SuperScript reverse transcription-PCR kit
(Invitrogen). Real time quantitative PCR (RT-qPCR) was performed
using a SYBR Premix Ex Taq kit (Takara, Shiga, Japan) and the iQ5
thermocycler (Bio-Rad). The efﬁciency of the used primers was eval-
uated by calculating the linear regression of Ct data points obtained
with a series of different primer dilutions and inferring the efﬁciency
from the slope of the line. We used the primers that gave efﬁciency
close to 100%. Primers for RT-qPCR are listed in Supplemental Table
1A. Quantiﬁcations were always normalized using endogenous con-
trol GAPDH.
2.9. Bioinformatic analysis of the human and mouse CDKL5 promoter
and chromatin immunoprecipitation (ChIP) Assay
5000 bp upstream and downstream the start site of the human
and mouse CDKL5 genomic sequence was analyzed for the presence
of MYCN canonical (CACGTG) and non canonical (CACGCG and
CATGTG) ebox and of SP1 binding site (GGGCGG) by the DNA analysis
software pDRAW32. Primer pairs were designed to amplify these re-
gions (see Supplementary Table 1B and Figs. 6 and 8).
Dual ChIP cross-linking was performed as previously described
[45]. The antibodies employed in this study were: IgG (sc-2027,
Santa Cruz); anti-MYCN monoclonal antibody (sc-53993, Santa
Cruz), and anti-SP1 (Upstate 07‐124). Speciﬁc pairs of primers used
for quantitative ChIP are listed in Supplementary Table 1B.
2.10. Luciferase assay
The pGL3-basic and Renilla-TK vectors were obtained from
Promega. Promoter regions of the CDKL5 gene were obtained using
PCR and cloned into the pGL3-basic vector. The activity of ﬁreﬂy orRenilla luciferase was measured with a dual luciferase assay kit
(Promega) according to the instructions.
2.11. Statistical analysis
Results are presented as the mean±standard error of the mean
(SEM). Statistical signiﬁcance was assessed by two-way analysis of
variance (ANOVA), followed by Bonferroni's post hoc test or by the
two-tailed Student's t-test. For the publicly available microarray
dataset, clinical, pathological, and gene expression data for 102 pri-
mary neuroblastoma tumors [31] were obtained through the http://
pob.abcc.ncifcrf.gov/cgi-bin/JK web site. Survival probabilities in neu-
roblastoma subgroups were estimated according to the methods of
Kaplan and Meier [13]. Survival distributions were compared using
log-rank tests [27]. A probability level of Pb0.05 was considered to
be statistically signiﬁcant.
3. Results
3.1. CDKL5 is up-regulated during neuroblatoma cell line differentiation
Neuroblastoma cells share several features with normal neurons
and thus are considered a good in vitro model to study the biochem-
ical and functional properties of neuronal cells, particularly when
they are induced to differentiate upon treatment with agents such
as retinoic acid (RA) [30,40]. For these reasons neurobastoma cells
have been here employed to study the CDKL5 function in vitro. We
ﬁrst sought to establish whether human neuroblastoma cell lines ex-
hibit a positive correlation between CDKL5 expression and neuronal
differentiation similar to those observed in vivo during brain develop-
ment [8,36]. We evaluated morphological differentiation and CDKL5
expression in two neuroblastoma cell lines, SH-SY5Y and SKNBE, fol-
lowing RA treatment. SH-SY5Y cells treated with RA resulted in a
quick and large change in their morphology when compared to
SKNBE cells kept under similar conditions. Within 3 days after addi-
tion of RA, SH-SY5Y cells extended long branched processes measur-
ing up to 5–6 fold the length of the cell body, while SKNBE cells were
still undifferentiated (Fig. 1A,B). Consistent with previous studies
[10], RA-mediated differentiation of SKNBE cells starts only after
7 days from RA exposure (Fig. 1A,B). Although basal CDKL5 expres-
sion was notably higher in untreated SH-SY5Y than in untreated
SKNBE cells (Fig. 1C), differentiating SH-SY5Y cells exhibited strong
up-regulation of CDKL5 expression (Fig. 1C), whereas SKNBE cells
did not show any change in CDKL5 expression within the same
RA-treatment period (Fig. 1C). The up-regulation of CDKL5 expres-
sion in differentiating SH-SY5Y cells was conﬁrmed also at the protein
level. We found that CDKL5 expression increased after 3 (+40%) and
7 (+100%) days of RA exposure (Fig. 1D). In our experimental condi-
tions, CDKL5 protein levels in SKNBE cells were below detection
limits (data not shown), conﬁrming the low basal expression of
CDKL5 in SKNBE compared to SH-SY5Y cells.
The correlation between CDKL5 expression and SH-SY5Y differen-
tiation indicates that SH-SY5Y neuroblastoma cells may represent a
suitable model to study the role of CDKL5 in neuronal proliferation/
differentiation.
3.2. CDKL5 promotes neuronal differentiation in the SH-SY5Y neuroblas-
toma cell line
To demonstrate that CDKL5 can play some role in neuronal differ-
entiation, we over-expressed the CDKL5 protein in SH-SY5Y cells by
transient transfection of a pGFP/CDKL5-FLAG expression vector (Sup-
plementary Fig. 1C — Analysis of the time-course of over-expression
of CDKL5-FLAG showed that it was highly expressed at 24 h after
transfection and that its expression was notably reduced at 72 h).
As CDKL5 has been reported to localize both in the nuclear and
Fig. 1. CDKL5 expression during differentiation in neuroblastoma cell lines. A: Immunoﬂuorescence images showing the morphology of SH-SY5Y (upper panel) and SKNBE (lower
panel) cells after 7 days of treatment with (+RA) or without (−RA) retinoic acid. Cells were stained for β-tubulin III (green) and nuclei were counterstained with Hoechst dye
(blue). Scale bar: 30 μm. B: Quantiﬁcation of neurite outgrowth of SH-SY5Y (upper histogram) and SKNBE (lower histogram) cells that were either untreated or treated with RA
(10 μM) for 3 and 7 days. Neurite outgrowth was expressed as mean neurite length (μm) per cell. Data are expressed as mean±SE of 4 independent experiments. A minimum
of 400 cells were evaluated in each experiment for each condition. *Pb0.05; ***Pb0.001, treated vs. untreated condition (Bonferroni's test after ANOVA). C: Quantiﬁcation by
RT-qPCR of CDKL5 expression in SH-SY5Y and SKNBE cells that were either untreated or treated with RA (10 μM) for 3 and 7 days. Data, given as percentage of untreated
SH-SY5Y cells, are expressed as mean±SE. The asterisks indicate a signiﬁcant difference between treated vs. untreated condition, *Pb0.05, ***Pb0.001 (Bonferroni's test after
ANOVA). D: CDKL5 protein expression in SH-SY5Y cells either untreated or treated with RA (10 μM) for 3 and 7 days was analyzed by immunoblot with a CDKL5 speciﬁc antibody.
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lular localization. As shown in Supplementary Fig. 1A, CDKL5 local-
ized in both the cytoplasm and the nucleus (Supplementary Fig. 1A,
panels). As previously reported [36,47], Western blot analysis of frac-
tionated extracts showed that CDKL5 was preferentially present in
the cytoplasm (Supplementary Fig. 1B).
We next examined neuritic growth in GFP- and GFP-CDKL5-
positive cells isolated by cell sorting 24 h after transfection and then
grown for 1–2 days either in the absence or presence of RA. We
found that CDKL5 was able to induce a beginning of differentiation,
as assessed by evaluation of neuritic length (Fig. 2A,B). While cellsexpressing GFP alone (controls) occasionally emitted very short pro-
cesses (Fig. 2B, left panel), cells expressing GFP-CDKL5 had longer
processes with a length increase by +100% after 2 days (Fig. 2A;
Fig. 2B, left panel). To analyse the effects of CDKL5 expression on
RA-induced differentiation, GFP- and GFP-CDKL5-positive cells were
cultured for 1–2 days in the presence of RA (Fig. 2A,B). After 1 day
of RA treatment, CDKL5 expressing cells exhibited a greater neurite
length as compared to control cells (+30%, Fig. 2A,B). This difference
was no longer detectable after 2 days of RA treatment (Fig. 2A,B). The
lack of difference between control and transfected cells after 2 days of
RA treatment (i.e. 72 h post transfection) is most likely attributable to
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Fig. 2. CDKL5 induces differentiation in the SH-SY5Y neuroblastoma cell line. A: Quantiﬁcation of neurite outgrowth of SH-SY5Y cells transfected with either GFP-CDKL5 or GFP.
Twenty four hours from transfection, cells were FACS sorted for GFP ﬂuorescence and cultured for 1–2 days with or without retinoic acid (RA; 10 μM). Neurite outgrowth was
expressed as mean neurite length (μm) per cell. Data are expressed as mean±SE of 3–4 independent experiments. A minimum of 400 cells were evaluated in each experiment
for each condition. The asterisks indicate a signiﬁcant difference between cells expressing GFP-CDKL5 vs. cells expressing GFP alone. ***Pb0.001; two-tailed t-test. B: Representative
phase-contrast images of cells expressing GFP-CDKL5 or GFP and cultured for 1 or 2 days in absence of RA (RA−) or in presence of 10 μM RA (RA+). Scale bar: 15 μm C: SH-SY5Y
cells were transfected with two different siRNA against CDKL5 (si1 and si2; 50 nM) or with scramble siRNA (siScr; 50 nM). Quantiﬁcation by Western blots of CDKL5 expression
was performed 48 h after transfection. D: Quantiﬁcation of neurite outgrowth of SH-SY5Y cells transfected with si1, si2 or siSCR (50 nM). Six hours after siRNA transfection cells
were treated with RA (10 μM) and analyzed 42 h later for neurite outgrowth. Data are expressed as mean±SE of 3 independent experiments. **Pb0.01, two-tailed t-test.
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mentary Fig. 1C). Though the effect of CDKL5 was smaller than that
induced by RA (Fig. 2A), these data clearly show that CDKL5 can pro-
mote neuronal differentiation in the absence of pro-differentiative
stimuli. To further corroborate this ﬁnding, we tested whether a
reduction in CDKL5 expression interfered with RA-induced differenti-
ation. To this purpose SH-SY5Y cells were transfected with two differ-
ent siRNAs against CDKL5 (si1, si2) to inhibit CDKL5 expression and
treated with RA. After 48 h of treatment, the reduced expression of
CDKL5 induced by the siRNAs against CDKL5 (−45% and −60%,
Fig. 2C) was paralleled by a reduction (−46% and −58%, Fig. 2D) in
neurite elongation. Transfection with a scrambled siRNA (siScr), as
negative control, had no effect on CDKL5 expression and RA-
induced cell differentiation (Fig. 2C,D).These data indicate that CDKL5 alone can trigger differentiation of
neuroblastoma cells and enhance the differentiation induced by RA,
conﬁrming the role of CDKL5 in neuron differentiation.
3.3. CDKL5 negatively regulates cell proliferation in the SH-SY5Y
neuroblastoma cell line
It has been previously shown that CDKL5 expression peaks dur-
ing late embryonic stage and the ﬁrst postnatal period [8], when
most of the neuronal progenitors stop proliferating and enter the
differentiated state, suggesting that it may negatively control neuron
proliferation. To address this point, SH-SY5Y cells transiently ex-
pressing the CDKL5-FLAG fusion protein were evaluated for prolifer-
ation rate by a bromodeoxyuridine (BrdU) incorporation assay, in
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S-phase of the cell cycle. The effect of CDKL5 on cell proliferation was de-
termined by evaluating the number of proliferating cells (BrdU positive
cells) that expressed CDKL5 (CDKL5-FLAG positive cells). Interestingly,
we could never observe cells that, in addition to express CDKL5, were
also BrdU positive, supporting our hypothesis that CDKL5 may inhibit
cell proliferation (Fig. 3A). As a further control, cells were also immuno-
stained for Ki-67 a typical proliferation marker that is expressed in cell
nuclei of dividing cells through late-G1+S+G2+M but not G0 and
early G1 phases of cell cycle [38]. As expected no CDKL5-positive cells
expressed Ki-67 (Fig. 3B). To exclude non-speciﬁc effects due to protein
over‐expression, SH-SY5Y cells were transfected with a CMV-FLAG-
Luciferase control vector.Wehave chosen Luciferase in that its expression
should not affect cell cycle dynamics. Indeed, we found that about 30% of
BrdU positive cells also expressed Luciferase (data not shown). Our data
indicate that CDKL5 over-expression speciﬁcally blocks cell proliferation
of neuroblatoma cells.
To conﬁrm the anti-proliferative role of CDKL5, the endogenous
expression of the protein was silenced using two siRNAs directed
against CDKL5 (si1, si2). We found that a reduced expression of
CDKL5 after siRNAs transfection corresponded to an increase in cell
proliferation (+31% si1, +39% si2, Fig. 3C), thus supporting the idea
that CDKL5 can inhibit cell proliferation. Treatment with a scrambledFig. 3. Effect of CDKL5 expression on proliferation in the SH-SY5Y neuroblastoma cell lin
CDKL5-FLAG. Twenty-four hours after transfection, SH-SY5Y cells were treated with BrdU (
Cells were immunostained for FLAG (red signal) and BrdU (green signal in A) or FLAG an
The arrows in Hoechst and merge images indicate the nuclei of cells expressing exogenous
were evaluated in each experiment for each condition. Scale bar: 20 μm. C: Labeling index (
for SH-SY5Y transfected two different siRNA against CDKL5 (si1 and si2; 50 nM) or with sc
BrdU (10 μM) for the last 2 h. Data, given as percentage of control condition, are expressedsiRNA (siScr), as negative control, had no effect on cell proliferation
(data not shown).
3.4. CDKL5 does not induce cell death in the SH-SY5Y neuroblastoma cell
line
We also investigated whether CDKL5 expression may trigger cell
death in neuroblastoma cells. When we evaluated the percentage of
apoptosis by immunostaining of intracellular cleaved caspase-3 we
found no difference in the number of apoptotic cells between
CDKL5 positive and negative cells (Fig. 4A,B), indicating that CDKL5
over-expression did not induce apoptotic cell death.
3.5. CDKL5 blocks cell cycle progression in the SH-SY5Y neuroblastoma
cell line
The fact that CDKL5 can inhibit proliferation leads us to speculate
that CDKL5 may affect the cell cycle dynamics. To clarify this point,
we compared the cell cycle proﬁle of GFP vs. GFP-CDKL5 transfected
SH-SY5Y cells. FACS sorted GFP positive cells (Fig. 4C) were treated
with propidium iodide to stain DNA and analyzed by ﬂow cytometry.
We found that the fraction of cells in G0/G1 was signiﬁcantly in-
creased in CDKL5 over-expressing cells as compared to control cellse. A,B: Immunoﬂuorescence images of SH-SY5Y neuroblastoma cells transfected with
10 μM) for 2 h and thereafter cells were processed for double immunocytochemistry.
d Ki-67 (green signal in B). Cell nuclei were stained with Hoechst dye (blue signal).
CDKL5. Three independent experiments were performed and a minimum of 600 cells
LI), deﬁned as percentage of BrdU positive cells over total cell number, was determined
ramble siRNA (siSCR; 50 nM). Forty six hours after transfection cells were exposed to
as mean±SE of 3 independent experiments. **Pb0.01; two-tailed t-test.
Fig. 4. Expression of CDKL5 does not induce cell death but blocks cell cycle progression in SH-SY5Y neuroblastoma cells. A: Example of immunoﬂuorescence image of SH-SY5Y neu-
roblastoma cells transfected with GFP-CDKL5. Twenty-four hours after transfection, SH-SY5Y cells were immunostained for cleaved caspase-3 (red signal). Cell nuclei were stained
with Hoechst dye (blue signal). Scale bar: 25 μm. B: Percentage of cleaved caspase-3-positive cells over total number of GFP-CDKL5-positive cells and GFP-positive cells. Data are
expressed as mean±SE of 3 independent experiments. A minimum of 450 cells were evaluated in each experiment for each condition. C: Twenty-four hours after transfection with
GFP-CDKL5 or GFP alone, SH-SY5Y cells were FACS sorted for GFP expression. The threshold for positivity for GFP was established as the levels corresponding to untransfected cells
(histogram on the left). The green area in the histogram on the right shows ﬂuorescence intensity of sorted GFP-CDKL5 positive cells. D: Distribution of cell populations in the G0/1,
S, or G2/M phases of the cell cycle, identiﬁed by ﬂow cytometry analysis. Data, given as percentage of either GFP-CDKL5 or GFP cells in each phase of the cell cycle, are expressed as
mean±SE of 3 independent experiments, *Pb0.05, **Pb0.01, two-tailed t-test.
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CDKL5 over-expressing cells, the percentage of G0/G1 became approx-
imately 70%, suggesting that CDKL5 blocks cells in G0/G1 phase
(Fig. 4D). We found no differences in the percentage of cells in the
sub-G1, which is considered to indicate the proportion of apoptotic
cells over total (data not shown), indicating that CDKL5 does not in-
duce apoptosis in neuroblastoma cells. These data suggest that the in-
hibition of cell proliferation following expression of exogenous CDKL5
is due to arrest in the G0/G1 phase of the cell cycle.
3.6. Inverse relationship between CDKL5 and MYCN expression in
neuroblastoma cell lines and neuroblastomas
The oncogeneMYCN is emerging as an important regulator of neu-
ron expansion during brain development that acts by increasing cell
proliferation and preventing cell differentiation [17,23]. Due to its
antiproliferative/prodifferentiative role, CDKL5 can be a good candi-
date as one of the gene negatively regulated by MYCN during braindevelopment. To determine a correlation between CDKL5 and MYCN
we evaluated CDKL5 expression in a MYCN ampliﬁed neuroblastoma
cell line (SKNBE) and in a MYCN non-ampliﬁed neuroblastoma cell
line (SH-SY5Y). CDKL5 expression was found to inversely correlate
with MYCN expression (Fig. 5A) and with the proliferation potency
of these cells (Fig. 5B). To rule out that the inverse relationship be-
tween CDKL5 and MYCN expression observed in the SKNBE and
SH-SY5Y cell lines is due to their different origins, we generated sta-
ble SH-SY5Y neuroblastoma cell clones expressing different levels of
MYCN protein. CDKL5 expression in the various SH-SY5Y-derived
cell lines showed a close inverse correlation with the levels of
MYCN expression (Fig. 5C). This suggests that MYCN over-
expression reduces CDKL5 expression. In agreement with the
pro-proliferative nature of MYCN, MYCN over‐expressing cell lines,
showed an increase in the proliferation rate that correlated with
MYCN expression levels (Fig. 5D). To conﬁrm the inverse relationship
between CDKL5 and MYCN expression, the conditional MYCN ex-
pressing SHEP Tet21/N cell line [26] was treated with tetracycline
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increase in CDKL5 expression (Fig. 5E) and a concomitant decrease
in cell proliferation (Fig. 5F), further supporting MYCN regulation of
CDKL5 expression.
A bioinformatic meta-analysis of human neuroblastoma
transcriptome databases [31]was used to further investigate CDKL5 ex-
pression in relation to MYCN expression. We found higher levels of
CDKL5 expression in neuroblastomas without MYCN ampliﬁcation
(n=11), comparedwith thosewithMYCN ampliﬁcation (n=34) (Sup-
plementary Fig. 2A), indicating that in neuroblastomapatients, similarly
to neuroblastoma cell lines, CDKL5 expression is inversely associated
with MYCN ampliﬁcation and expression. Kaplan–Meier survivalFig. 5. Inverse relationship between MYCN and CDKL5 expression. A: Quantiﬁcation by RT-q
of SH-SY5Y and SKNBE cells. Cell cultures were treated with BrdU for 2 h and processed
BrdU-positive cells over total cell number, identiﬁed by Hoechst staining. C: Quantiﬁcatio
engineered to express higher levels of MYCN (+MYCN, ++MYCN). D: LI of SH-SY5Y, SH-S
CDKL5 expression in Tet21/N neuroblastoma cells treated or untreated with tetracycline (
expressed as mean±SE of 3 independent experiments. **Pb0.01, ***Pb0.001, two-tailed t-analysis shows that a high CDKL5 expression is associated with a good
disease outcome of neuroblastomas (Supplementary Fig. 2B), which is
in line with the anti-proliferative role of CDKL5 demonstrated here in
neuroblastoma cell lines.
3.7. CDKL5 expression is transcriptionally inhibited by MYCN
It has been recently shown that MYCN can bind and repress gene
transcription by interacting with the transcription factor SP1 [34].
Bioinformatic analysis showed an SP1-rich region proximal to the
start site of the CDKL5 promoter. Dual ChIP assay was performed in
a SH-SY5Y cell clone engineered to constitutively express high levelsPCR of MYCN and CDKL5 expression in SH-SY5Y and SKNBE cells. B: Labeling index (LI)
for immunoﬂuorescence with an anti-BrdU antibody. LI is deﬁned as the number of
n by RT-qPCR of MYCN and CDKL5 expression in SH-SY5Y cells and in SH-SY5Y cells
Y5Y(+MYCN) and SH-SY5Y(++MYCN). E: Quantiﬁcation, by RT-qPCR, of MYCN and
TET). F: LI of Tet21/N neuroblastoma cells treated as reported in (E). Data in A–F are
test.
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SP1-reach region of the CDKL5 promoter (Fig. 6). As expected, a
strong binding of SP1 was also present in the same region (Fig. 6).
To establish whether MYCN can regulate CDKL5 at the promoter
level, CDKL5 reporter promoter constructs were transiently transfected
into Tet21/N (+MYCN) and Tet21/N (−MYCN) cells. CDKL5 promoter
constructs incorporating the SP1-reach region exhibited a signiﬁcant
reduction in the Luciferase activity in the presence of MYCN (+MYCN
cells), indicating thatMYCN inhibits CDKL5 transcription (Fig. 7). A pro-
moter construct limited to the SP1-reach regionwas indeed sufﬁcient to
inhibit transcription, indicating that MYCN could inhibit CDKL5 tran-
scription through the SP1-reach region, possibly by interacting with
SP1 as previously established [28]. The extent of MYCN-mediated re-
pression was comparable to that observed for the ABCC3 promoter
(Fig. 7), another gene known to be repressed byMYCN through interac-
tion with SP1.
3.8. MYCN-dependent CDKL5 expression in primary cerebellar granule
cells
We have recently shown that cerebellar granule cell precursors
(GCPs) exhibit high levels of MYCN expression, that progressively de-
crease with granule cell differentiation both in vivo and in vitro
[10,11]. To establish whether an inverse relationship between
MYCN and CDKL5 expression is present in neuronal precursors, we
measured their expression in primary cultures of cerebellar granule
cells (CGCs) before and after in vitro differentiation. These cells are a
homogeneous neuronal population (90–95% of the total cells in the
culture) that replicates many of the biochemical and physiologicalFig. 6. MYCN binds CDKL5 promoter. Dual cross-linking ChIP was performed in SH-SY5Y(++
pre-immune serum (IgG), anti-SP1 and anti-MYCN antibodies. Real-time PCR of immunopre
regions overlapping MYCN-canonical or non canonical binding site (Amplicons B,C,E) or SP1
lected DNA regions of the human CDKL5 gene promoter, calculated as the logarithm of the d
and the cycle-threshold obtained with the speciﬁc antibody. The panel on the left shows the
agarose gel and visualized by ethidium bromide. Values represent mean±SE of three exper
promoter with indicated the positions of the SP1 and MYCN canonical and non-canonical bfeatures of native cerebellar development. GCPs undergo differentia-
tion during the ﬁrst week in culture and a fully differentiated state
is reached by 7 days in vitro (DIV). We found that in freshly dissociat-
ed GCPs (DIV0) there was a higher expression of MYCN than after in-
duction of differentiation (DIV 7) (Fig. 8A). Conversely, CDKL5
expression was lower at DIV0 than at DIV 7 (Fig. 8B). In parallel, as
previously reported [10], proliferation was completely inhibited in
differentiated CGCs (Fig. 8C).
To establish whether the inverse relationship between MycN and
Cdkl5 protein expression during CGC differentiation underlies a
MycN-dependent transcriptional inhibition of Cdkl5 expression, we
performed ChIP experiments on undifferentiated CGPs vs. differenti-
ated CGCs. Bioinformatic analysis of the mouse Cdkl5 gene promoter
identiﬁed, similarly to the human CDKL5 promoter, one region proxi-
mal to the transcription start site enriched for Sp1-binding sites
(Fig. 8D). Dual cross-linking ChIP assay in CGPs showed that anti-
bodies against MycN and Sp1 can efﬁciently immunoprecipitate the
region of Cdkl5 gene promoter carrying Sp1-binding sites (Fig. 8D).
In contrast, no MycN-enrichment was found in differentiated CGCs
(Fig. 8D). These data conﬁrm a direct role of MycN on CDKL5 expres-
sion in primary neurons.
4. Discussion
In spite of the clear importance of CDKL5 for the central nervous
system, the biological functions of this kinase remain largely un-
known. Here we show for the ﬁrst time that this gene affects both
proliferation and differentiation of neural cells. Moreover, our results
show that CDKL5 expression is regulated by MYCN and suggest thatMYCN) neuroblastoma cells. DNA/protein complexes were immunoprecipitated with
cipitated DNA with primers targeting the negative control region (Amplicon A) or four
-binding sites (Amplicon D) were performed. The graphs show fold enrichment of se-
ifference between the cycle-threshold obtained with pre-immune serum (IgG control)
DNA Amplicons obtained by quantitative PCR at the 30th cycle of reaction, run on a 2%
iments. The lower scheme gives a schematic representation of the human CDKL5 gene
inding sites.
Fig. 7.MYCN inhibits CDKL5 expression. Tet21/N neuroblastoma cells were transfected with luciferase reporter constructs containing different regions of the CDKL5 promoter. The
cloned DNA regions (bp) are indicated below the promoter map. The ﬁreﬂy luciferase activity was determined in the presence (+TET) or absence (−TET) of MYCN expression.
Luciferase reporter analysis of ABCC3 promoter is shown as control. The results are the means±SE of three independent transfections.
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tion and differentiation of neural precursors.
4.1. CDKL5 induces differentiation and inhibits proliferation of the SH-SY5Y
neuroblastoma cell line
We provide evidence that in the SH-SY5Y neuroblastoma cell line
there is a direct correlation between neurite elongation and CDKL5
expression. This is consistent with recent lines of evidence showing
that CDKL5 regulates neurite growth and dendritic arborization of
cortical rat neurons [8]. Our data strengthen the role of CDKL5 during
development as a pro-differentiating gene. Impaired brain develop-
ment, including dendritic pathology and synaptic imbalance between
excitatory and inhibitory neurons, may contribute to epilepsy. There
are a number of neurodevelopment disorders, such as RTT, Fragile X
syndrome and Down syndrome, that directly affect dendritic struc-
ture, and which have a very high prevalence of epilepsy. Our ﬁnding
that CDKL5 is important for neuronal maturation provides novel evi-
dence for cellular mechanisms that may contribute to the EIEE2 dis-
ease phenotypes.
We found that in the SH-SY5Y cell line induction of CDKL5 expres-
sion caused a strong inhibition of cell proliferation with no increase in
apoptotic cell death. Inhibition of proliferation was due to a block of
cell cycle progression in the G0/1 phase, supporting the view that
CDKL5 can function as an anti-proliferative gene. A recent study
showed that CDKL5 is highly expressed in some clinical samples of
adult T-cell leukemia (ATL) and in several ATL cell lines [20]. The
role played by CDKL5 on cell proliferation in these and other tumor
cells remains to be established.
Because neuronal differentiation requires the progenitor to exit
the cell cycle, it is generally assumed that the processes of prolifera-
tion and differentiation are co-regulated. These processes intersect
at the regulation of cell cycle regulatory proteins. Proliferation pro-
motes positive regulation of cell cycle proteins (e.g. cyclins andcyclin-dependent kinases (Cdk)), whereas differentiation results in
inhibition of these cell cycle proteins [32]. Progression of the cell
cycle to the G0 phase leads to the cell cycle exit and differentiation.
Our ﬁndings show that CDKL5 acts both as a cell cycle inhibitor and
a pro-differentiating gene and are in line with several arguments
supporting a general interdependence of proliferation and differenti-
ation control. Very recently, it has been shown that induced Pluripo-
tent Stem Cells (iPSCs) from CDKL5 mutated patients can be
differentiated into neurons [1], suggesting that CDKL5 is not per se
necessary for acquisition of a neuronal phenotype and that CDKL5
mediated differentiation may be a secondary effect of the CDKL5
block of cells in the G0–G1 phase. For this reason CDKL5-mutated
iPSCs could be a suitable model to conﬁrm the anti-proliferative and
pro-differentiative role of CDKL5 in human neuronal cells, found
here in a neuroblastoma cell line.
Consistently with data in other cell lines and in vivo, we found
that CDKL5 localizes both at the cytoplasmic and nuclear level
[8,36]. The cytoplasmic localization of CDKL5 and its catalytic activity
are essential for the effects of this kinase on dendritic maturation [8].
CDKL5 appears to interact with nuclear factors, such as MeCP2 [24,28]
and DNA methyltransferase I [19], and associates with nuclear
speckles involved in RNA splicing [35]. It remains to be established
whether CDKL5 nuclear localization plays a role in the observed reg-
ulation of cell proliferation.
4.2. CDKL5 is a target of MYCN
While the vast majority of studies on MYCN have been conducted
in tumor cells, growing evidence suggests a key role for MYCN during
both murine and human brain development [23,43]. During brain de-
velopment, MYCN plays an important role to direct brain growth
[17,23], consistently with its widespread expression pattern. In agree-
ment with the pro-proliferative role of MYCN, conditional disruption
of Mycn in neural precursor cells severely disrupts brain growth,
Fig. 8. Inverse relationship between MYCN and CDKL5 expression in CGPs. A,B: Quantiﬁcation by RT-qPCR of MYCN (A) and CDKL5 (B) expression in freshly dissociated cerebellar
granular cell precursors (DIV0) and after 7 days in vitro (DIV7). Data, in A and B are given as percentage of DIV0 condition and are expressed as the mean ± SE of 3 independent
experiments. ***Pb0.001; two-tailed t-test. C: Labeling index (LI) was determined for cerebellar granular cells 3 h after plating (indicated as DIV0) and at DIV7. Cultures were treat-
ed with BrdU for 2 h, ﬁxed and processed for immunoﬂuorescence with an anti-BrdU antibody. Data are expressed as mean±SE. ***Pb0.001, two-tailed t-test. D: Dual cross-linking
ChIP and quantitative RT-PCR were applied in either freshly dissociated cerebellar granular precursors (DIV0) or after 7 days in vitro (DIV7). Real-time PCR with primers targeting
the negative control region (Amplicon mA) or four regions overlapping MYCN-canonical or non canonical binding site (amplicons mB–mD) or SP1-binding sites (amplicons mB,mE)
were performed. Fold enrichment of mouse Cdkl5 promoter regions immunoprecipitated by pre-immune serum (IgG), anti-SP1 and anti-MYCN antibodies was calculated as the
logarithm of the difference between the cycle-threshold obtained with pre-immune serum and the cycle-threshold obtained with the speciﬁc antibody. Schematic representation
of the mouse Cdkl5 gene promoter containing the SP1 binding sites.
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indicates a role for MYCN during brain development, the mechanisms
remain somewhat unclear.
By using stable and conditional cell lines that express high and low
levels of MYCN, we found that inhibition of MYCN expression corre-
lated to marked increase of CDKL5 expression. Conversely, inductionof MYCN expression led to inhibition of CDKL5 expression. Although
MYCN activates transcription of pro-proliferative cellular networks,
it is increasingly clear that it may exert its pro-proliferative action
also through repression of speciﬁc target genes. Our data indicate
that MYCN binds with the CDKL5 promoter region that is recognized
by SP1 and represses CDKL5 expression. This is consistent with recent
1184 E. Valli et al. / Biochimica et Biophysica Acta 1819 (2012) 1173–1185evidence showing that a direct inhibitory interaction between MYC
and SP1 can promote repression of several genes involved in cell
cycle control and differentiation [16]. Our study establishes a func-
tional axis between MYCN and CDKL5 in which MYCN antagonizes
the pro-differentiation activity of CDKL5 during neuron maturation.
MYCN plays a central role in the biology of neuroblastoma and
several other cancers as a driving oncogene for tumorigenesis [39].
MYCN ampliﬁcation remains the strongest negative prognostic indi-
cator for neuroblastoma [12]. Interestingly, the Kaplan–Meier surviv-
al analysis shows that CDKL5 expression correlates with less
aggressive tumors (Supplementary Fig. 2B), suggesting that the ex-
pression of CDKL5 may be a favorable predictor of clinical outcome.
This hypothesis is fully in agreement with the anti-proliferative role
of CDKL5 observed here in neuroblastoma cell lines. The present
work raises the issue of whether MYCN may contribute to the pro-
gression of neuroblastoma though repression of CDKL5 expression.
Future studies, exploiting the transgenic MYCN mouse model
TH-MYCN, a native neuroblastoma model in which tumorigenesis is
driven by targeted expression of MYCN in the neural crest [46],
would help understand the MYCN-CDKL5 relationship in the neuro-
blastoma pathogenesis, in vivo.
4.3. The MYCN/CDKL5 system appears to be involved in cerebellar
development
MYCN appears to play an important role in cerebellar develop-
ment. It promotes rapid cell division of cerebellar granule neural pre-
cursors [21,22] and in Mycn-KO mice there is a strong reduction in
the number of cerebellar granule precursors and mature granule neu-
rons [23]. The search for genes that are regulated by MYC has yielded
several hundred candidates. Recently, at least a dozen microarray-
based screens, mostly in tumors, have added over 600 genes to the
list of potential MYC targets [33]. With a few notable exceptions,
these kinds of studies have not identiﬁed genes that have obvious
links to the physiological processes typically associated with MYC
functions (for example, cell-cycle progression and maintenance of
pluripotency).
The expression of CDKL5 in the cerebellum has been shown to be
only minimally detectable at embryonic stage E16.5, but to be strong-
ly up-regulated in differentiating cerebellar granule cells, during
postnatal development [36]. This expression pattern suggests that
CDKL5 may be one of the genes regulated by MYCN, involved in the
shift from proliferation to differentiation of cerebellar granule cell
precursors. Consistently with this idea, we found a relatively low ex-
pression of CDKL5 in granule cell precursors at 0 DIV, a time at which
there was a high expression of MYCN, and a strong increase after 7
DIV, concomitantly with a reduction in the expression of MYCN. At
this stage, neurons have reached what is considered under several pa-
rameters a differentiate state, comparable to that of in vivo granule
cells. The expression pattern of the MYCN/CDKL5 system during dif-
ferentiation of cerebellar granule cells is in line with that observed
in differentiating neuroblastoma cells. Taken together our data sug-
gest that the MYCN-inhibition of CDKL5 expression may be a general-
ized mechanism across different neuronal precursors.
4.4. Conclusion
The connection between CDKL5 mutation genotype and disease
phenotype is hindered by the lack of information regarding the role
of CDKL5 in neuronal development and function. Our ﬁnding that
CDKL5 is important for neuronal proliferation/differentiation pro-
vides novel evidence for cellular mechanisms that may contribute to
the EIEE2 disease phenotypes.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbagrm.2012.08.001.Acknowledgements
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